FDA Brief

Warning letters Devices

FDA warning letter to

Nihon Kohden Digital Health Solutions, LLC

High riskIssued Jun 12Posted Jul 14Center for Devices and Radiological Health

FDA says Nihon Kohden Digital Health Solutions sold an uncleared monitor software change that can silence life-threatening alarms.

What happened

FDA inspected the Irvine, CA firm from February 23 to 24, 2026 and reviewed its Next Generation NetKonnect software device, a patient monitor with an arrhythmia detector and alarm. FDA found the firm added a Silence Alarms function in an October 22, 2022 software change and decided on its own that no new 510(k) clearance was needed. FDA also found the firm markets the device as compatible with other manufacturers' devices, which goes beyond the intended use cleared under K220989.

What FDA found

  1. The firm added a Silence Alarms function, which FDA considers a change to how the user controls the device, without getting a new 510(k) clearance first.

    21 CFR 807.81(a)(3)(i)
  2. FDA says this change could cause alarms to be missed for life-threatening conditions, leading to serious injury or death.

    21 CFR 807.81(a)(3)(i)
  3. The firm labels the device as working with any brand of computer and with other manufacturers' devices, an intended-use change beyond what was cleared under K220989, again without a new 510(k).

    21 CFR 807.81(a)(3)(ii)
  4. The device is adulterated because the firm has no approved premarket approval (PMA) application, which is FDA's full premarket review for higher-risk devices, or approved investigational device exemption.

    Section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)
  5. The device is misbranded because the firm did not tell FDA before starting commercial distribution, as the 510(k) premarket notification process requires.

    Section 502(o) of the Act, 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)

What FDA wants

FDA tells the firm to write back within fifteen business days describing the specific steps taken to fix the violations, how it will prevent them from recurring, and documentation of those corrections. If fixes will take longer, the firm must explain the delay and give a timetable.

Who should pay attention

  • hospitals and clinicians using NetKonnect monitors for patient alarms
  • device makers adding alarm controls or new input compatibility through software changes
  • regulatory affairs teams that decide whether a change needs a new 510(k)

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  4. Tides Medical LLC

    FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.

    High risk